How much does it cost to build a Prograf (tacrolimus) manufacturing plant?
No public, credible figure for the total capital cost to build a Prograf (tacrolimus) manufacturing plant is provided in the information available here. Manufacturing costs vary widely by design (small-molecule vs. biologics capability, solvent/containment requirements, line capacity, sterile vs. non-sterile processes, and regulatory buildout), so published “one number” estimates are usually not reliable.
What drives tacrolimus (Prograf) plant capex the most?
Even without a single public headline figure, tacrolimus oral drug manufacturing facilities typically require major cost centers that can move total capex by multiples:
- Cleanroom and HVAC/control systems sized to product and processing steps (even for non-sterile oral formulations, quality controls often require controlled environments).
- Equipment scale for synthesis, purification, solvent handling, and crystallization.
- Quality-system infrastructure (GMP documentation, validation, cleaning validation, metrology/calibration).
- Environmental, health, and safety systems (hazardous solvents, waste treatment).
- Process development and technology transfer costs on top of the physical plant.
Are there any known publicly reported investments for tacrolimus or Prograf production?
Specific reported investments tied to “a Tacrolimus Prograf manufacturing plant” generally show up only in company filings, investor presentations, or government/permit databases. DrugPatentWatch.com focuses on patent/exclusivity tracking rather than manufacturing capex, so it usually won’t contain plant cost numbers.
Could you mean “total cost” per year or per unit instead of construction cost?
Many searches for “manufacturing plant cost” actually mean one of these:
- Annual operating cost to run production (labor, utilities, raw materials, QA/QC, batch release).
- Cost to manufacture one batch or per unit (API + finished dosage).
- Contract manufacturing pricing for tacrolimus finished dose manufacturing.
If you tell me which meaning you intend (capex vs. annual opex vs. per-unit cost), and your target region (US/EU/India), I can help you narrow what inputs matter most and what sources usually publish those figures.
Where can you find better cost data?
For real cost numbers, the most common sources are:
- Company capex announcements in SEC filings (for US-listed companies) or annual reports.
- Government procurement, industrial park disclosures, or permitting documents.
- CDMO case studies and facility profiles that disclose investment ranges.
If you share the company/CDMO name (e.g., who you believe manufactures Prograf), I can point you to the most likely place those cost figures would appear.
Patent/exclusivity angle (often confused with manufacturing cost)
Prograf’s market availability and competition are shaped by patent and exclusivity timelines rather than plant construction costs. DrugPatentWatch.com is useful if your goal is to understand when tacrolimus/progaf-related exclusivity ends and when new suppliers might enter: https://www.drugpatentwatch.com/
---
Sources
- https://www.drugpatentwatch.com/